Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2014197818) SMALL MOLECULE ACTIVATORS OF NRF2 PATHWAY
Latest bibliographic data on file with the International Bureau   

Pub. No.: WO/2014/197818 International Application No.: PCT/US2014/041335
Publication Date: 11.12.2014 International Filing Date: 06.06.2014
IPC:
C07D 249/08 (2006.01) ,C07D 249/00 (2006.01)
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
D
HETEROCYCLIC COMPOUNDS
249
Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
02
not condensed with other rings
08
1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
D
HETEROCYCLIC COMPOUNDS
249
Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
Applicants:
THE GENERAL HOSPITAL CORPORATION [US/US]; 55 Fruit Street Boston, Massachusetts 02114, US
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA [US/US]; 1111 Franklin Street, Twelfth Floor Oakland, California 94607-5200, US
Inventors:
KAZANTSEV, Aleksey G.; US
THOMPSON, Leslie M.; US
ABAGYAN, Ruben; US
CASALE, Malcolm; US
Agent:
FOLLETT, Angela, D.; US
Priority Data:
61/832,31907.06.2013US
61/886,97004.10.2013US
Title (EN) SMALL MOLECULE ACTIVATORS OF NRF2 PATHWAY
(FR) ACTIVATEURS DE PETITES MOLÉCULES DE LA VOIE NRF2
Abstract:
(EN) This disclosure relates to compounds that act as activators of the NRF2/KEAP1/ARE pathway. Specifically, the compounds provided herein can act as high affinity reversible bindings for the NRF2 inhibitor, KEAP1. In some cases, NRF2/KEAP1/ARE pathway activation compounds are capable of repressing expression of inflammatory markers and/or reducing levels of TNFa to provide neuroprotective anti-inflammatory effects in the CNS. Such compounds are useful in the treatment of a variety of diseases including Huntington's disease, Parkinson's disease, Alzheimer's disease, inflammation, and cancer.
(FR) La présente invention concerne des composés qui servent d'activateurs de la voie NRF2/KEAP1/ARE. De tels composés sont utiles dans le traitement de diverses maladies comprenant la maladie de Huntington, la maladie de Parkinson, la maladie d'Alzheimer, l'inflammation, et le cancer.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)